Greatview Aseptic Packaging Company Limited – Investor Update: Deep Dive into 2025 Annual Report

Key Developments and Price-Sensitive Issues for Shareholders

The 2025 Annual Report of Greatview Aseptic Packaging Company Limited reveals a year marked by significant corporate events, internal investigations, control changes, and regulatory compliance challenges. These developments are highly material and may impact the Company’s share value and investor confidence.

1. Majority Stake Acquisition and Public Float Issue

• In February 2025, the Offeror and its Concert Parties acquired approximately 97.76% of the Company’s issued shares, dramatically reducing the public float to only 2.24%. This is well below the minimum 25% public float required by Hong Kong Stock Exchange (HKEX) rules.
• As a result, trading in the shares was suspended on 19 February 2025, and remains suspended pending restoration of the public float. The Company has applied for a temporary waiver but faces a deadline—if public float is not restored by 18 August 2026, the Company’s listing is at risk of cancellation.
• This situation is highly price-sensitive, as the suspension and potential delisting could significantly impact shareholder value and liquidity.

2. Special Investigation into Past Transactions and Governance Failures

• A Special Investigation Committee was established to scrutinize the 2024 Restructuring involving the International Business, due to allegations regarding consolidation accounting, related party transactions, and undisclosed financial arrangements.
• The investigation revealed:
  • Questionable accounting treatment of the International Business post-Restructuring, with the basis for consolidation appearing unsupported.
  • Potential manipulation of financial data to avoid classifying the Restructuring as a major transaction (which would have required shareholder approval). This was done by carving out the Egypt and Lebanon businesses, and adjusting bad debt provisions to keep size test ratios below regulatory thresholds.
  • Discovery of undisclosed related party transactions, improper use of company funds (including RMB6.5 million in interest-free loans to directors and RMB300,000 in unrelated expenditures), and inadequate disclosure of financial product purchases exceeding 5% of total assets.
  • Internal control deficiencies, including lack of policies for key procedures, inadequate approvals, and insufficient record-keeping.
• These findings are highly material, as they raise questions over past management’s integrity, regulatory compliance, and the accuracy of prior disclosures.

3. Remedial Actions and Board Response

• The Company has accepted the findings of the investigations and has taken significant remedial actions:
  • Appointment of BT Corporate Governance Limited as Internal Control Consultant, with all recommendations for strengthening controls, policies, and procedures now implemented.
  • Initiation of legal proceedings to unwind the problematic 2024 Restructuring and recovery of company assets.
  • Full review and disclosure of previously undisclosed related party transactions and connected transactions as per HKEX Listing Rules.
  • Reconstitution of the Board and senior management, with a renewed commitment to compliance, transparency, and robust corporate governance.
• The Board asserts that remedial actions have rectified the major control weaknesses and that the Company is now compliant with Listing Rules, but continued monitoring and reporting to regulators and shareholders will be necessary.

4. Financial Highlights and Dividend Policy

• Dividends: Despite the turbulent year, the Board recommends a final dividend of HK\$0.006 per share (RMB7.6 million in total), significantly down from HK\$0.22 per share previously. The dividend will be paid on or around 6 August 2026, subject to shareholder approval.
• Gearing Ratio: The Company maintains a low gearing ratio of 3%, indicating prudent financial management.

5. Key Risks and Outlook

• High Customer Concentration: The top five customers account for 60% of revenue, exposing the Company to concentration risk.
• Ongoing Regulatory Scrutiny: The Company must comply with all HKEX resumption guidance and Listing Rules to avoid delisting.
• Internal Control and Governance: The Company has overhauled its risk management, whistleblowing, and anti-corruption policies, with regular reviews and audits.

Key Takeaways for Investors

• The Company is in a critical recovery phase after a period of serious governance lapses and regulatory breaches.
• Share trading is suspended, with the risk of delisting if the public float is not restored by August 2026.
• Major remedial actions have been implemented, but ongoing regulatory, legal, and reputational risks remain.
• The significant reduction in dividend underscores the impact of the year’s events on shareholder returns.

Disclaimer: This article is provided for information purposes only and does not constitute investment advice. Investors should refer to the full Annual Report and consult professional advisors before making investment decisions. The Company’s shares are currently suspended from trading and face the risk of delisting. The information herein is based on the 2025 Annual Report and subsequent official announcements.

View GAPACK Historical chart here